-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
-
Summary
-
Ambrx Biopharma Cayman, Inc. quarterly/annual General and Administrative Expense history and change rate from 2019 to Q2 2023.
- Ambrx Biopharma Cayman, Inc. General and Administrative Expense for the quarter ending 30 Jun 2023 was $5,900,000.000, a 22.3% increase year-over-year.
- Ambrx Biopharma Cayman, Inc. annual General and Administrative Expense for 2022 was $20,836,000.000, a 22.1% increase from 2021.
- Ambrx Biopharma Cayman, Inc. annual General and Administrative Expense for 2021 was $17,071,000.000, a 169% increase from 2020.
- Ambrx Biopharma Cayman, Inc. annual General and Administrative Expense for 2020 was $6,353,000.000, a 0.73% decline from 2019.
General and Administrative Expense, Quarterly (USD)
General and Administrative Expense, YoY Quarterly Change (%)
General and Administrative Expense, Annual (USD)
General and Administrative Expense, YoY Annual Change (%)